Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

• OBJECTIVES: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios. RESULTS: At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05). CONCLUSIONS: P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials.

Nyckelord

Aged

Aged

80 and over

Alzheimer Disease

cerebrospinal fluid

diagnosis

Amyloid beta-Protein

analysis

cerebrospinal fluid

Biological Markers

analysis

cerebrospinal fluid

Cognition Disorders

cerebrospinal fluid

diagnosis

Cohort Studies

Disease Progression

Early Diagnosis

Female

Humans

Isoprostanes

analysis

cerebrospinal fluid

Longitudinal Studies

Male

Middle Aged

Peptide Fragments

analysis

cerebrospinal fluid

Predictive Value of Tests

Prognosis

tau Proteins

analysis

cerebrospinal fluid

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)